-
-
-
-
-
-
-
Pfizer's BRAFTOVI regimen shows improved survival in colorectal cancer
-
-
-
-
-
-
-
U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
-
-
-
-
-
-
-
U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer
-
-
-
-
-
-
-
Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial
-
-
-
-
-
-
-
PADCEV-Keytruda combo shows survival benefit in bladder cancer trial
-
-
-
-
-
-
-
FDA approves PADCEV plus Keytruda for bladder cancer patients
-
-
-
-
-
-
-
Pfizer Responds to Delaware Chancery Court Ruling
-
1,169,797 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

